SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/08719D5D2535B1C0828957C63F3B0680660BF6731899243605720A1C9C69E11F8A279C354695A09E9C084E0689F70516>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/08719D5D2535B1C0828957C63F3B0680660BF6731899243605720A1C9C69E11F8A279C354695A09E9C084E0689F70516
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/08719D5D2535B1C0828957C63F3B0680660BF6731899243605720A1C9C69E11F8A279C354695A09E9C084E0689F70516
http://www.w3.org/2000/01/rdf-schema#comment
"Studies showed the qualitative and quantitative expression of four target surface antigens CD19 CD20 CD22 and CD33 for which MoAbs are currently available for clinical use in ALL."
xsd:string
http://purl.uniprot.org/uniprot/#_9B56775E9782FBE40AA74557CDF5F8C56F3A76521822CB41352242B448A37ED1C242674FEA64221AC09AF77233FA56AC
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/08719D5D2535B1C0828957C63F3B0680660BF6731899243605720A1C9C69E11F8A279C354695A09E9C084E0689F70516
http://purl.uniprot.org/uniprot/Q546G0
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/08719D5D2535B1C0828957C63F3B0680660BF6731899243605720A1C9C69E11F8A279C354695A09E9C084E0689F70516
http://purl.uniprot.org/uniprot/#_Q546G0-mappedCitation-21348573
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/08719D5D2535B1C0828957C63F3B0680660BF6731899243605720A1C9C69E11F8A279C354695A09E9C084E0689F70516